Department of Radiation Oncology, Apollo Proton Cancer Centre, Chennai, Tamil Nadu, India.
Department of Medical Physics, Apollo Proton Cancer Centre, Chennai, Tamil Nadu, India.
Radiat Oncol. 2022 Jun 30;17(1):115. doi: 10.1186/s13014-022-02085-4.
To report our experience with image guided pencil beam proton beam therapy (PBT) for craniospinal irradiation (CSI).
Between January 2019 and December 2021, we carried out a detailed audit of the first forty patients treated with PBT. We had recorded acute toxicities, reporting early outcomes and discuss limitations of current contouring guidelines during CSI PBT planning.
Median age of the patient cohort was 8 years, and histologies include 20 medulloblastoma, 7 recurrent ependymoma, 3 pineoblastoma, 3 were germ cell tumors and remaining 7 constituted other diagnoses. Forty percent patients received concurrent chemotherapy. Median CSI dose was 23.4 Gy (Gray; range 21.6-35 Gy). Thirty-five patients (87.5%) completed their CSI without interruption, 5 required hospital admission. No patient had grade 2/ > weight loss during the treatment. Forty-five percent (18) developed grade 1 haematological toxicities and 20% (8) developed grade 2 or 3 toxicities; none had grade 4 toxicities. At median follow up of 12 months, 90% patients are alive of whom 88.9% are having local control. Special consideration with modification in standard contouring used at our institute helped in limiting acute toxicities in paediatric CSI patients.
Our preliminary experience with modern contemporary PBT using pencil beam technology and daily image guidance in a range of tumours suitable for CSI is encouraging. Patients tolerated the treatment well with acceptable acute toxicity and expected short-term survival outcome. In paediatric CSI patients, modification in standard contouring guidelines required to achieve better results with PBT.
报告我们使用笔形束质子束治疗(PBT)进行颅脊髓照射(CSI)的经验。
在 2019 年 1 月至 2021 年 12 月期间,我们对接受 PBT 治疗的前 40 名患者进行了详细的审核。我们记录了急性毒性反应,报告了早期结果,并讨论了 CSI PBT 计划中当前轮廓指南的局限性。
患者队列的中位年龄为 8 岁,组织学包括 20 例髓母细胞瘤、7 例复发性室管膜瘤、3 例成松果体细胞瘤、3 例生殖细胞瘤和其余 7 例为其他诊断。40%的患者接受了同期化疗。CSI 剂量中位数为 23.4Gy(戈瑞;范围 21.6-35Gy)。35 名患者(87.5%)完成了 CSI 治疗,没有中断,5 名患者需要住院治疗。治疗过程中没有患者出现 2/>体重减轻的 2 级毒性。45%(18 例)出现 1 级血液学毒性,20%(8 例)出现 2 级或 3 级毒性;没有 4 级毒性。在 12 个月的中位随访期内,90%的患者存活,其中 88.9%的患者局部控制。在我们研究所使用的标准轮廓修改特殊考虑有助于限制小儿 CSI 患者的急性毒性。
我们使用铅笔束技术和每日图像引导的现代当代 PBT 在一系列适合 CSI 的肿瘤中的初步经验令人鼓舞。患者耐受治疗的能力良好,急性毒性可接受,预期短期生存结果良好。在小儿 CSI 患者中,需要修改标准轮廓指南,以实现更好的 PBT 结果。